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Background: Approximately 20% of children with sickle cell disease (SCD) have micro-
albuminuria (MA). Very little is known about the progression of MA in children and young 
adults with SCD.
Methods: In this study, we analyzed 5-year EMR data of 373 children [with ≥2 micro-
albumin-to-creatinine (MA/Cr) ratio measurements] followed at the Medical University 
of South Carolina to determine the rate, direction, magnitude, and predictors of MA/Cr 
change over time.
results: Age range was 1–22  years; mean 10.2 ±  5.2  years, 49.5% were males. 
Median follow-up duration was 3.12 ± 1.16 years. At baseline, 328 children had normal 
(<20 mg/L) MA level. Forty-five (12.1%) of children had MA (≥20 mg/L), of which 91% 
were ≥8 years and 21 (47%) continued to have MA at the end of the study period. On the 
other hand, during the study period, 24 new patients developed MA and 24 normalized 
their MA to levels <20 mg/L. In multivariate logistic regression model, age and bilirubin 
levels were predictive of MA/Cr increase in patients who received at least one blood 
transfusion during the study period. Baseline MA level was not predictive of the change 
in MA/Cr.
conclusion: In children and young adults, microalbuminuria is considered a marker of 
early renal injury. Over time, MA/Cr levels may increase or decrease. Further studies are 
needed to confirm our findings, assess the reliability of MA as marker of long-term renal 
injury, and identify high risk patients with SCD likely to have worsening of MA over time.
Keywords: microalbuminuria, progression, sickle cell nephropathy, children, young adults
inTrODUcTiOn
Sickle cell disease (SCD) affects more than 100,000 African-Americans (AA) in the United States. 
The single gene mutation causes distortion of red blood cells, which impairs oxygen delivery to 
every organ in the body. The entire nephron is affected by endothelial dysfunction, vaso-occlusion, 
ischemia, infarction, and ultimately nephron loss. Evidence of renal disease begins early in child-
hood and often progresses to chronic kidney disease (CKD) in adults (1).
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A mild to moderate increase of urinary albumin has a high 
prevalence in patients with diabetes mellitus, hypertension, and 
chronic kidney disease (2, 3). This so-called microalbuminuria 
appears to be a risk marker for renal and cardiovascular diseases 
later in life (4, 5).
The improved survival of patients with SCD has led to an 
increase in the incidence of nephropathy, along with other target-
organ damage, which often causes end-stage renal failure (1, 6, 7). 
The average age of renal failure is 40 years, but early signs, such 
as microalbuminuria, may be apparent in childhood (1). In fact, 
the prevalence of microalbuminuria or proteinuria in children 
with SCD has been shown to range from 18 to 28%. Though it can 
be intermittent in an individual, there is a correlation between 
MA levels and increasing age and decreasing hemoglobin levels 
in children and adolescents with SCD (8–13). To our knowledge, 
this is the first large pediatric study which aims to study pro-
gression and predictors of urinary microalbumin-to-creatinine 
change over time.
PaTienTs anD MeThODs
study Population and Variables
This is a retrospective analysis of data from the Medical University 
of South Carolina (MUSC) EMR for the years 2009–2014. 
Children with SCD followed at the MUSC pediatric sickle cell 
disease clinic (the largest program in the state of SC) were identi-
fied from the EMR using relevant ICD-9 codes (282.41, 282.42, 
282.60, 282.61, 282.62, 282.63, 282.64, 282.68, and 282.69); 
duplicates were excluded by matching to medical record number 
before de-identification. Children and young adults 1–22 years of 
age with the diagnosis of sickle cell disease with at least two MA/
Cr measurements were included in this study.
At MUSC, a protocol for urine MA/Cr screening was started 
in 2008 to collect midstream urine samples at routine follow-up 
visits at the Sickle cell clinic, measurements were avoided within 
2 weeks of hospitalization, any form of vaso-occlusive crises, or 
febrile illnesses.
Three hundred seventy-three children and young adult unique 
patients met the above criteria. To assess for magnitude and direc-
tion of change (i.e., increase or decrease) in microalbuminuria 
levels over time, the ratio of urinary microalbumin to urinary 
creatinine (MA/Cr) in micrograms per milligram was calculated 
and utilized for all patients. For clinical practice, microalbumi-
nuria (MA) was defined as Urine MA of ≥20 mg/L (14). In this 
manuscript, MA refers to the absolute measurement known to 
define clinical microalbuminuria, while MA/Cr refers to the 
ratio used in this manuscript to standardize measurements and 
correct for different urinary samples concentration/dilution as 
well as allow us to compare measurements overtime. The first 
MA/Cr measurement during the study period was considered 
the baseline, and the last measurement during the study period 
was utilized as the last MA/Cr. The rate of change in MA/Cr is 
expressed as micrograms per milligram per year. The study was 
approved by the MUSC Institutional Review Board.
Demographic and bioclinical variables collected from 
EMR and included in the current study include age, sex, urine 
MA, urine creatinine, total bilirubin, reticulocyte count and 
percentage, serum albumin, serum creatinine, hemoglobin, 
LDH, baseline hemoglobin electrophoresis results, transfusion 
history, hemochromatosis diagnosis, and medication use. For 
statistical analysis purposes and clinical plausibility, medications 
were grouped into four groups: ACEi/ARB, hydroxyurea, both 
ACEi/ARB and hydroxyurea, and other.
All samples collected during the study period were analyzed at 
the MUSC clinical laboratory using the same technology. Urinary 
albumin levels were measured using a solid-phase fluorescent 
immunoassay. Urinary creatinine levels were measured by using 
the Jaffe rate reaction with a CX3 analyzer (Beckman ASTRA, 
Brea, CA, USA).
statistical analysis
Statistical tests of significance between MA/Cr categories were 
determined using Student’s t-test or chi square test for continu-
ous and dichotomous variables, respectively. Participant demo-
graphic characteristics and laboratory measures were compared 
by change in MA/Cr (increase or decrease). Based on clinical 
plausibility and statistical significance, demographic and/or labo-
ratory determinants were entered into the multivariate logistic 
regression and used to examine of change in MA classification 
(outcome variable). There was a significant interaction between 
age and the history of receiving at least one blood transfusion. To 
test the hypothesis that history of transfusion affected change in 
MA/Cr, a product interaction term was calculated by multiplying 
history of interaction (dichotomous) with continuous age and 
entered into the multivariate model. Data were analyzed using 
Stata (SE 13.1; College Station, TX, USA). A p-value of <0.05 was 
considered statistically significant.
resUlTs
Three hundred seventy-three children and young adults with sickle 
cell disease who had ≥2 MA/Cr measurements were included in 
this study. Age range was 1–22 years; mean 10.21 (5.23), 49.5% 
were males. Mean follow-up time was 3.12 ± 1.16 years. At base-
line, 328 children had normal (<20 mg/L) MA level. Forty-five 
(12.1%) of children had MA (≥20  mg/L), of which 91% were 
≥8 years and 21 (47%) continued to have MA at the end of the 
study period. During the study period, 24 new patients developed 
MA and 24 normalized their MA to levels <20 mg/L.
To study the direction and magnitude of change in MA over the 
study period, MA/Cr (micrograms per milligram) was calculated. 
The study population was categorized based on the direction of 
MA/Cr change over time (increase or decrease). Almost one-half 
(46%) of the study population (n = 174) had worsening of the 
MA/Cr levels with a median absolute change of 3 μg/mg (1, 11) 
and a mean rate of 20 μg/mg/year (Table 1). On the other hand, 
54% (n = 199) had improvement in their MA/Cr with a median 
absolute change of −4  μg/mg (−10, −2) and a mean rate of 
10 μg/mg/year.
Children who developed worsening MA/Cr were significantly 
more likely to be older (10.86 ± 5.25 years; p = 0.02) and have a 
lower Hb F but not higher Hb S.
There were no statistically significant differences in the 
reticulocyte count or percentage, albumin, serum creatinine, 
TaBle 2 | Predictors of worsening Ma/cr levels stratified by transfusion 
history during the study period.
Variable Or p 95% conf. interval
received blood transfusion
Age 1.12 <0.01 1.06–1.19
Sex 1.35 0.32 0.74–2.46
Bilirubin 0.81 0.01 0.69–0.95
no blood transfusion
Age 1.01 0.85 0.94–1.07
Sex 1.80 0.06 0.98–3.29
Bilirubin 0.86 0.20 0.69–1.08
OR, odds ratio; stratified: p for interaction age × transfusion = 0.01.
TaBle 1 | characteristics of study population by direction of Ma/cr change.
Urine Ma/cr decrease  
53.35% (n = 199)
Urine Ma/cr increase  
46.65% (n = 174)
Total  
n = 373
p-value
Time, years between first and last 3.13 (1.19) 3.12 (1.12) 3.12 (1.16) 0.93
Urine MA/Cr change median (25th, 75th ‰), µg/mg −4 (−10, −2) 3 (1, 11) −1 (−4, 2) <0.001
Age, years (SD) 9.64 ( 5.16) 10.86 ( 5.25) 10.21 (5.23) 0.03
Sex (male), % (n) 48.91 (90) 51.09 (94) 49.46 (184) 0.10
Serum albumin, g/dL (SD) 4.09 (0.30) 4.09 (0.29) 4.09 (0.30) 0.97
Serum creatinine mg/dL (SD) 0.43 (0.18) 0.45 (0.17) 0.44 (0.18) 0.34
Hemoglobin, g/dL (SD) 9.34 (1.78) 9.34 (1.63) 9.34 (1.71) 0.98
Hemoglobin A2, % (SD) 3.67 (0.85) 3.68 (0.93) 3.67 (0.88) 0.97
Hemoglobin F, % (SD) 9.09 (7.99) 7.43 (7.17) 8.32 (7.65) 0.04
Hemoglobin S, % (SD) 67.01 (19.60) 63.37 (20.39) 65.31 (20.02) 0.08
Total bilirubin, mg/dL (SD) 2.55 (2.29) 2.26 (2.00) 2.42 (2.00) 0.16
First (baseline) MA/Cr, µg/mg 30 (103) 16 (57) 23 (85) 0.11
Last MA/Cr, µg/mg 11 (29) 100 (642) 53 (440) 0.05
Blood transfusion, yes % (n) 49.75 (99) 55.75 (97) 52.55 (196) 0.25
ACEi/ARB, yes % (n) 3.52 (7) 6.32 (11) 4.83 (18) 0.21
Hydroxyurea, yes % (n) 13.07 (26) 16.09 (28) 14.48 (54) 0.41
Both ACEi/ARB and hydroxyurea 2.51 (5) 2.30 (4) 2.41 (9) 1.00
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hemoglobin, hemoglobin A2, total bilirubin levels, or medication 
(ACEi/ARBs, hydroxyurea) use between the MA/Cr groups.
There was a significant interaction between age and the his-
tory of receiving at least one blood transfusion (p = 0.013). In 
multivariate logistic regression model stratified by history of 
transfusion, age and total bilirubin levels were predictive of wors-
ening MA/Cr levels in patients who received at least one blood 
transfusion during the study period. Baseline MA level was not 
predictive of the change in MA/Cr (Table 2).
DiscUssiOn
Renal injury starts early in life in patients with SCD. The kidney’s 
medullary environment is one of relative hypoxia, acidosis, and 
hypertonicity, all conditions that favor red blood cell sickling 
and hemoglobin S polymerization. It is thought that repeated 
vaso-occlusive events in the vasa recta lead to an ischemic–
hyperperfusion-type injury, characterized pathologically by early 
glomerular enlargement followed by eventual focal segmental 
glomerulosclerosis, the most common cause of renal failure in 
SCD (1, 6, 15, 16).
As a consequence, younger patients with SCD have an 
increased glomerular filtration rate (GFR) and renal plasma 
flow, both of which normalize in adolescence and decrease in 
adulthood as a result of the scarring (17, 18). Proteinuria is the 
most common clinical manifestation of these changes of sickle 
nephropathy. Recently, a large number of studies have described 
the prevalence and correlates of microalbuminuria as an early 
marker of renal injury. To our knowledge, there are no longitudi-
nal studies examining changes in MA levels in children with SCD. 
This is the first large pediatric study to assess the progression of 
MA levels (corrected to urinary creatinine levels) and to examine 
predictors of change over time in a cohort of patients with SCD. 
In this study, we report that MA/Cr levels can change both ways 
over time, almost one-half of the study population (n =  174) 
developed worsening MA/Cr. Older children were more likely 
to have MA (p = 0.03). Ninety-one percent of children with MA 
were 8 years of age or older. Age and bilirubin levels were predic-
tive of MA/Cr level increase in children who received one or more 
blood transfusions during the study period.
Very little is known about MA rate of progression in children 
with SCD (8). Previously, we have reported the prevalence of MA 
in a pediatric cohort to be 15.5% (10). In the present study, the 
prevalence of MA was lower at 12.1% possibly due to the inclu-
sion of younger children in the study cohort. Gosmanova and 
colleagues reported the prevalence and progression of MA and 
CKD over 5-year follow-up in 98 adults with SCD (19). In their 
study, the prevalence of abnormal albuminuria at baseline was 
26.5% but subsequently increased to 42.8% after 5 years of follow-
up. Most of the patients with abnormal albuminuria at baseline 
(65.4%) had unchanged, whereas a smaller number (11.5%) of 
patients progressed to a higher albuminuria grade, and 23.1% of 
patients regressed to a lower albuminuria grade. These findings 
are consistent with our findings that in a subset of children with 
SCD, MA may improve with time. This may reflect improved 
hemodynamic forces in the glomerulus, repair of tubular injury, 
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resolution of systemic inflammation, ischemia reperfusion injury, 
or possibly withdrawal of offending medications. That being said, 
almost one-half of the study population developed worsening of 
the MA/Cr levels.
Other studies have defined MA as levels ≥30 μg/mg, using 
this cutoff level to reexamine our cohort, all (except 3) patients 
(n = 42) whom were diagnosed to have MA in our study had lev-
els above ≥30 μg/mg. Of whom, 69% has worsening of their MA 
levels by the end of the study, and in 31%, MA levels improved 
although did not normalize. It is also important to point out that 
multiple studies examining different patient populations have 
demonstrated good correlation between spot urine MA/Cr and 
24-h urinary albumin excretion in children (20).
While examining the predictors of MA/Cr progression, we 
found a significant interaction between age and blood transfusion 
history, which necessitated stratifying the statistical models by 
transfusion history. Children with history of one or more blood 
transfusion during the study period (probably sicker children 
with possibly more frequent crises, increased transcranial 
Doppler velocities, more severe anemia, and hemolysis requiring 
blood transfusion) were more likely to have worsening of MA/Cr 
if they were older and/or had higher bilirubin levels.
Among clinical correlates and predictors of MA that we 
and others have previously described are increasing age, lower 
hemoglobin levels, increased markers of hemolysis (10), such 
as reticulocyte count, indirect bilirubin level, and serum hap-
toglobin, and LDH levels (21). In this study, there were no sta-
tistically significant differences in the reticulocyte percentage or 
count, hemoglobin, hemoglobin A2, and bilirubin levels between 
the groups of worsening MA/Cr vs. improved MA/Cr levels. On 
the other hand, lower Hb F but not higher Hb S was associated 
with increasing MA/Cr levels; this is consistent with findings 
published by Lebensburger et al. showing protective role of fetal 
hemoglobin in early kidney disease for children with sickle cell 
anemia (22).
In children with SCD, age correlation to MA levels is well 
described, although the strength of the association varies (9, 11, 
12, 23–25). In this study, age positively correlated with urinary 
albumin excretion (p  =  0.03). The NHLBI Evidence-Based 
Management of Sickle Cell Disease Expert Panel Report, 2014, 
recommended screening all individuals with SCD, beginning by 
age 10, for proteinuria. If the result is negative, repeat screening 
annually. If the result is positive, perform first morning void urine 
albumin–creatinine ratio and if abnormal, consult with or refer 
to a renal specialist. For adults with MA without other appar-
ent cause, the guidelines recommend to initiate angiotensin-
converting enzyme (ACE) inhibitor therapy with moderate 
quality evidence (26). Although our study was not designed to 
determine a cutoff age for MA screening in children with SCD, 
91% of children with MA were 8 years of age or older. Whether 
patients will benefit from screening at an earlier age using MA 
measurements or should clinician only screen with urinalysis or 
urine dipstick to avoid over diagnosing a condition (MA) that 
may improve with time remains to be answered.
Studies of therapeutic interventions, including ACE inhibi-
tor and hydroxyurea therapy (HU), to reduce MA are limited, 
small, and retrospective. Although hydroxyurea treatment was 
associated with a decrease in hyperfiltration and LDH levels in 
the HUSTLE study, its effects on cystatin C and MA were not 
significant (27). A more recent study in 58 adults with SCD found 
6 months of hydroxyurea treatment to reduce MA levels (28). On 
the other hand, in general, studies examining ACEi and ARB 
treatment demonstrated reduction in MA levels, keeping in mind 
those studies were limited by small sample size and duration of 
follow-up (8, 9, 16, 29, 30). A small proportion of our cohort 
received hydroxyurea or ACEi/ARB or both treatments during 
the study period; the number of subjects who received these treat-
ments was comparable between the MA increase vs. MA decrease 
groups (Table 1). While short trials of ACEi showed beneficial 
effects on reduction of MA levels, using such treatments for 
extended periods of time raise multiple questions. For example, 
are the effects of such treatment long-lived or transient? Does 
reduction of MA levels translate to reduction in long-term risk 
of ESRD or CKD progression? Do such treatments raise the risk 
of AKI and/or hyperkalemia in this “at risk” patient population? 
How big of an impact do these agents have on blood pressure 
in children with SCD? A large prospective study designed and 
powered to examine the safety and efficacy of long-term treat-
ment with these agents is needed (9, 16, 30–32).
Our study is limited by the retrospective study design utiliz-
ing data from the EMR. The data set did not have certain sickle 
cell comorbidity diagnosis (number of acute chest syndrome 
and other crises hospitalizations, history of stroke, or abnormal 
transcranial Doppler velocities); such comorbidities reflect to 
a certain degree the disease severity. To help assess for disease 
severity, variables, such as markers of hemolysis and history of 
blood transfusion, were included in our analysis. Our data set 
did not have growth and nutrition (anthropometric data) and 
cardiovascular parameters, variables that should be included 
in future prospective studies. We relied on ICD-9 codes to 
identify patients with sickle cell disease from our EMR, this 
possibly introduced errors related to coding. Our clinic staff 
was instructed to collect midstream first urine samples, the fact 
that this is a retrospective study using EMR data carries the pos-
sibility that patients (children) scheduled for clinic visits later 
in the day may have provided samples otherwise. Our study 
has multiple strengths, including the availability of longitudinal 
data on a relatively large cohort and the availability of both MA 
and urinary creatinine levels, which allowed us to accurately 
compare levels over the study period. In addition, all samples 
were collected analyzed at the one institution and using the same 
equipment.
Urinary microalbumin levels are considered to be one of the 
early renal injury markers in patients with sickle cell disease. 
Testing for it is non-invasive, readily available, and easy to per-
form in most of the clinical settings. Our study suggests that in 
children with SCD, MA levels may increase or decrease over time. 
The relationship between MA and SCD is a complex one with 
multiple cardiovascular and anthropometric confounding fac-
tors. Understanding the prevalence, significance, and the natural 
history of MA as well as identifying the subset of patients with 
SCD who are at risk of disease progression will allow us to target 
this high risk group with potential therapeutic interventions aim-
ing at early renal protection.
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glOssarY
Microalbuminuria (MA): urinary albumin measuring 20 mg/L or 
more on spot urine sample.
MA/Cr: microalbumin-to-creatinine ratio measured in 
micrograms of albumin to milligrams of creatinine.
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